Author:
Kelly Zahra R.,Gorantla Vikram C.,Davar Diwakar
Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. NCI NCI. Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969–2017) [Internet]. 2018 [cited 2018]. Available from: www.seer.cancer.gov/popdata. Accessed 1 May 2020.
2. Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–23.
3. Weber J, Mandala M, Vecchio MD, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. New Engl J Med. 2017;377:1824–35.
4. Eggermont A, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801. https://doi.org/10.1056/NEJMoa1802357.
5. Weber J, et al. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial. Ann Oncol. 2019:v533–4. https://doi.org/10.1093/annonc/mdz255.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献